Literature DB >> 15356818

Staphylococcus aureus with reduced susceptibility to vancomycin.

S E Cosgrove1, K C Carroll, T M Perl.   

Abstract

Infections with Staphylococcus aureus with reduced susceptibility to vancomycin continue to be reported, including 2 cases caused by S. aureus isolates with full resistance to vancomycin. This review first outlines the definitions of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) and risk factors for infection. Next, we describe the mechanisms of resistance and methods of laboratory detection of the organisms. Finally, we address infection control and management issues associated with isolation of VISA and VRSA.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15356818     DOI： 10.1086/422458

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  33 in total

1.  Exposure of Staphylococcus aureus to Targocil Blocks Translocation of the Major Autolysin Atl across the Membrane, Resulting in a Significant Decrease in Autolysis.

Authors:  Kiran B Tiwari; Craig Gatto; Suzanne Walker; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Painful nodule with induration and spreading erythema.

Authors:  Elizabeth Race; Cindy Berthelot; Jennifer Clay Cather
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

Review 3.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

4.  Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.

Authors:  Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.

Authors:  Miki Matsuo; Longzhu Cui; Jeeyoung Kim; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

6.  Development of a broad spectrum polymer-released antimicrobial coating for the prevention of resistant strain bacterial infections.

Authors:  K D Sinclair; T X Pham; R W Farnsworth; D L Williams; C Loc-Carrillo; L A Horne; S H Ingebretsen; R D Bloebaum
Journal:  J Biomed Mater Res A       Date:  2012-05-24       Impact factor: 4.396

Review 7.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

Review 8.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

Authors:  W T Prince; Z Ivezic-Schoenfeld; C Lell; K J Tack; R Novak; F Obermayr; G H Talbot
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

10.  Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR.

Authors:  Yoshihisa Kato; Takahisa Suzuki; Takashi Ida; Kazunori Maebashi
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.